General Information


Genprex™ is a clinical stage gene therapy company developing a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Employees: 4
Founded: 2009
Contact Information
Address 100 Congress Avenue, Suite 2000 Austin, TX, 78701, US
Phone Number (512) 370-4081
Web Address
View Prospectus: Genprex
Financial Information
Market Cap $65.2mil
Revenues $0 mil (last 12 months)
Net Income $-3.6 mil (last 12 months)
IPO Profile
Symbol GNPX
Exchange NASDAQ
Shares (millions): 1.3
Price range $5.00 - $5.00
Est. $ Volume $6.4 mil
Manager / Joint Managers Network 1 Financial Securities
CO-Managers -
Expected To Trade: 3/29/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change